Dundee researchers bring pioneering Parkinson’s trial to local patients
Dundee Culture9 Oct · 01:24← All topics · now
Development ↘
Development ↘
Development ↘
Development ↘
Development ↘
Development ↘
Right now
A phase 3 Parkinson’s drug trial has met its main goal.
23 reports · the last 24 hours
Summary · from headlines6 points
- Studies found microglia can protect vulnerable dopamine neurons by removing toxic α-synuclein aggregates.
- Studies linked greater physical activity with slower Parkinson’s progression and long-term cognitive and motor benefits.
- A first single-cell DNA analysis revealed mitochondrial damage in vulnerable Parkinson’s brainstem neurons.
- A report found Parkinson’s traits vary by sex, from motor issues to smell loss.
- Solengepras met the primary endpoint in the Phase 3 ARISE trial of Parkinson disease.
- Dundee researchers are bringing a pioneering Parkinson’s trial to local patients.
Latest developments6 to read first
‘Absolutely staggering’: Results from experimental drug trial to prevent Parkinson’s disease
SMH.com.au9 Oct · 01:24Parkinson’s Pill Met Goals in Late-Stage Trial, Cerevance Says
Bloomberg.com9 Oct · 01:24Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease
NeurologyLive9 Oct · 01:24UC study correlates increased physical activity with slower Parkinson’s progression
University of Cincinnati8 Oct · 23:04From Motor Issues to Smell Loss: How PD Traits Vary by Sex
Medscape8 Oct · 21:04Timeline 23 reports
9 Oct 20264 reportsToday
01:004 reports
8 Oct 202619 reports
23:001 report
22:00nothing heard
21:001 report
20:00nothing heard
19:001 report
18:001 report
17:003 reports
16:00nothing heard
15:00nothing heard
14:00nothing heard
13:00nothing heard
12:00nothing heard
11:00nothing heard
10:00nothing heard
09:00nothing heard
08:00nothing heard
07:00nothing heard
06:00nothing heard
05:001 report
04:006 reports
03:005 reports
← All topics · nowOne topic